תפריט ראשי עליון

תפריט עמוד

Dr. Anat Aharon

Director, Hematology Research Laboratory, Tel Aviv medical center

Anat Aharon
Schedule an appointment

Education

​

  • 2/2018- Director, Hematology Research Laboratory, Tel Aviv medical center
  • 2004-1/2018   Director, Microvesicle Research Laboratory, Department of Hematology and Bone        Marrow Transplantation, Rambam Health Care Campus 
  • 2016- 1/2018  Member of the Clinical Research Institute at Rambam (CRIR)
  • 2012-2014    CEO (50%), MPT Ltd. MPT Ltd – Micro-Particles technology - dedícate to bringing a  simple, eficiente and cost effective blood test of the mother for prenatal genetic testing
  • 2002-04       Beth Israel Deaconess Medical Center, Boston, MA, USA,  Postdoctoral fellowship
  • 2000-02 Bruce Rappaport Medical School, Technion, Israel's Institute of Technology. Haifa, Israel,  Instructor, Hematology for medicine students.

​

  • 2019-Present Senior Lecturer,  faculty of medicine, Tel Aviv University 
  • 20015-2018     Assistant  Professor , Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of  Technology, Haifa, Israel
  • 2010-2014      Associated Senior Lecturer faculty of medicine – Technion, Israel`s Institute of   Technology, Haifa, Israel 
  • 2005-2010       Associated lecture faculty of medicine, Technion, Israel`s Institute of Technology, Haifa, Israel


Basic science

1. Zarfati M, Avivi I, Brenner B, Katz T, Aharon A. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis. November 2018
2. Levin C, Koren A, Rebibo-Sabbah A, Koifman N, Brenner B, Aharon A. Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis. Front Physiol. 2018;9:1214.
3. Aharon  A,  Rebibo Sabbah A. Issman L. BerkovichH. Copty R. Talmon Y, Brenner B. Effects of Low- and High-Dose Chemotherapy Agents on Thrombogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines Thrombosis and Hemostasis march 2018
4. Eliyahu S, Aharon A, Bianco-Peled H. Acrylated Chitosan Nanoparticles with Enhanced Mucoadhesion, Polymers 2018, 10, 106; doi:10.3390/polym10020106 (registering DOI)
5. Aharon  A,  Sabbah A, Ben-Shaul S, Berkovic H, David Loven D, Brenner B and Bar-Sela B. Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function. Oncotarget 2017 8:63265-63280
1. Aharon  A,  Sabbah A, Issman L,  Berkovic H, Stern H, Abboud Y, Talmon Y, Brenner B.   Effects of Low- and High-Dose Chemotherapy on Tumorigenic, Thrombogenic and Angiogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines. –Submitted to Breast Cancer Research, April  2017 
2. Koifman N, Biran I, Aharon A, Brenner B, Talmon Y. A direct-imaging cryo-EM study of shedding extracellular vesicles from leukemic monocytes. J Struct Biol. 2017 S1047-8477(17) 30021-7
3. Kohli S, Hoffmann J, Lochmann F, Markmeyer P, Huebner H, Fahlbusch FB, Al-Dabet MM, Gadi I, Manoharan J, Löttge M, Zenclussen AC, Aharon A, Brenner B, Shahzad K, Ruebner M, Isermann B. p45 NF-E2 regulates syncytiotrophoblast differentiation by post-translational GCM1 modifications in human intrauterine growth restriction. Cell Death Dis. 2017 6;8:e2730
4. Kohli S, Ranjan S, Hoffmann J, Kashif M, Daniel EA, Al-Dabet MM, Bock F, Nazir S, Huebner H, Mertens PR, Fischer KD, Zenclussen AC, Offermanns S, Aharon A, Brenner B, Shahzad K, Ruebner M, Isermann B.  Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts.  Blood. 2016;128:2153-2164
5. Zarfati M, Katz T, Avivi I, Brenner B, Aharon A. PO-45 - The role of microvesicles in multiple myeloma progression. Thromb Res. 2016 
6. Tzoran I, Rebibo-Sabbah A, Brenner B, Aharon A. PO-46 - Influence of extracellular vesicles derived from AML patients on stem cells and their microenvironment. Thromb Res. 2016 .
7. Shomer E, Katzenella S, Zipori Y,  Rebibo-Sabbahd A, Brenner B,  Aharon A. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function. Thromb Res. 2016;137:141-7.
8. Tzoran I, Rebibo-Sabbah A. Brenner B, Aharon, A.  Disease dynamics in patients with acute myeloid leukaemia: new biomarkers. Excepted for publication in Exp Hematol. 2015;43:936-43
9. Shomer E, Katzenell S, Zipori Y, Sammour RN, Isermann B, Brenner B, Aharon A. Microvesicles of Women With Gestational Hypertension and Preeclampsia Affect Human Trophoblast Fate and Endothelial Function. Hypertension. 2013; 62: 893-8.
10. Issman L., Brenner B. , Talmon Y. Aharon A. Cryogenic Transmission Electron Microscopy Nanostructural Study of Shed Microparticles PLOS one 2013 ;8:e83680.
11. Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y. Tumor-derived microparticles induce bone marrow derived cell mobilization and tumor homing: a process regulated by osteopontin. Int J Cancer. 2014;135:270-81
12. Katzenell S, Shomer E, Zylberfisz A,  Zipori Y,  Brenner B, Aharon A. Characterization of negatively charged phospholipids and cell origin of microparticles in women with gestational vascular complications Thromb Res. 2012;130:479-84. 
13. Tsimerman G., Roguin A., Bachar A, Melamed E., Brenner B, Aharon A. Involvement of microparticles in diabetic vascular complications Thromb Haemost. 2011;106:310-21. 
14. Hamed S, Alshiek J, Aharon A, Brenner B, Roguin A. Red wine consumption improves in vitro migration of endothelial progenitor cells in young, healthy individuals. Am J Clin Nutr.2010;92:161-9.
15. Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A. Hyperglycemia and Oxidized-LDL exert a deleterious effect on Endothelial Progenitor Cell migration in Type 2 Diabetes Mellitus. Thromb Res. 2010;126:166-74.
16. Hamed S, Brenner B, Aharon A, Daoud D, Roguin A. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2009;8:56.
17. Aharon A, Katzenell S, Tamari T, Brenner B. Tissue factor- and tissue factor pathway inhibitor-bearing microparticles in gestational vascular complications. JTH 2009;7:1047-1050.
18. Aharon A, Tal Tamari, Brenner B.  Monocyte derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost. 2008;100:878-85.
19. Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost. 2005;3:2355-7
20. Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells - implications for placental hemostasis. Thromb Haemost. 2004; 92:776-786.
21. Kraiem Z, Sadeh O, Yosef M, Aharon A. Mutual antagonistic interactions between the thyrotropin (adenosine 3',5'-monophosphate) and protein kinase C/epidermal growth factor (tyrosine kinase) pathways in cell proliferation and differentiation of cultured human thyroid follicles. Endocrinology.1995;136:585-90.

Review papers

1. Aharon A, Brenner B. Microvesicles in Thrombosis and Inflammation. Isr Med Assoc J. 2016;18:530-533
2. Aharon A.  The role of extracellular vesicles in placental vascular complications. Thromb Res.  Volume 135, Supplement 1, Pages S23–S25.
3. Aharon A, Rebibo-Sabbah A, Tzoran I, Levin C.  Extracellular Vesicles in Hematological Disorders Rambam Maimonides Medical Journal 2014; 5: e0032
4. Greer IA, Aharon A, Brenner B, Gris JC. Coagulation and placenta-mediated complications. Rambam Maimonides Med J. 2014 ;5: e0034
5. Aharon A, Brenner B. Placenta-derived microparticles. Thromb Res. 2013 Jan;131 Suppl 1:S22-4.
6. Aharon A, Brenner B. Microparticles and pregnancy complications Thromb Res. 2011 3:S67-71
7. Aharon A. Brenner B. Microparticles and Placental Hemostasis. Thromb Res. 2009;123 Suppl 2:S88-92
8. Aharon A. Brenner B.  Microparticles, thrombosis and cancer. Best Practice & Research Clinical Haematology  2009; 22: 61-69
9. Brenner B, Aharon A. Thrombophilia and adverse pregnancy outcome Clin Perinatol. 2007;34:527-41
10. B. Brenner, A. Aharon, N. Lanir  Hemostasis in normal pregnancy. Thromb Res. 2005;115 Suppl1:6-10
11. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost. 2003; 29:175-184
12. Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta Best Pract Res Clin Haematol. 2003; 16:183-195.

Books Chapter

1. HEMOSTASIS AND THROMBOSIS BASIC PRINCIPLES AND CLINICAL PRACTICE, SIXTH EDITION, Chapter 118):  Title:  “Spontaneous fetal loss“. Aharon A, Gris J.C, Brenner B. 2012
2. Thrombophilia in Pregnancy. Bailliere’s Best Practice & Research, Clinical Haematology. Hemostatic mechanisms in human placenta (Brenner B, Lanir N, Aharon A). 16(2):183-195, 2003



​

  • 2011  The 2011 Rambam Medical Center Research Award, for the study "Microparticles effect on Apoptosis, Angiogenesis and Migration in Healthy and Pathological Pregnancies".
  • 2005  Aventis/ ISTH thrombosis research - fellowship award for basic research. "The role of microparticles in gestational vascular complications (GVC) and their possible modulation by enoxaparin"
  • 2002 The Boston-Haifa Research Award for the study "Characterization and   function of microparticles in the placenta’s local haemostatic balance by - in vitro and in vivo models."
  • 2001 The 2001 Rambam Medical Center Research Award, for the study "Procoagulant and anti coagulant mechanisms in human placenta."




  • ISTH-International Society on Thrombosis and Haemostasis, Inc
  • European and Mediterranean League against Thrombotic Diseases -EMLTD
  • ISEV- The International Society for Extracellular Vesicles
  • Hematologic Society Israel 
  • AACR - American Association for Cancer Research

​Extracellular Vesicles (EVs) are small (≈1 µm) cellular membrane vesicles shed from various cells upon stimulation or apoptosis. EVs are found in blood of healthy individuals and their levels increase in a variety of diseases (cancer, diabetes, vascular diseases, etc.). EVs are involved in physiological processes but they can also promote pathological states. Over the last 15 years Dr. Aharon and her team have studied the role of EVs in healthy persons and in patient with gestational vascular complications, diabetes vascular complications, cancer (hematological malignancies: myeloma, AML, ALL and solid tumors such as breast cancer, colon cancer), in congenital disorders such as thalassemia and in trauma patients and patients with dementia. Furthermore, the effects of EVs that are shed from cell culture upon stimulation on functionality of endothelial cells as well as placental cells, liver, pancreatic and breast cancer cell lines were explored. Additionally the therapeutic potential of EVs in chronic GVHD is currently being invested

תפריט ניווט תחתון